	US 12,440,501 B2
	Cannabinoid compositions and methods of use thereof for immune modulation
Akhil Alugupalli, Horsham, PA (US); and Kishore Alugupalli, Horsham, PA (US)
Assigned to SRIN Therapeutics, Inc., Horsham, PA (US)
Appl. No. 17/428,572
Filed by SRIN Therapeutics, Inc., Horsham, PA (US)
PCT Filed Feb. 7, 2020, PCT No. PCT/US2020/017311 § 371(c)(1), (2) Date Aug. 4, 2021, PCT Pub. No. WO2020/163775, PCT Pub. Date Aug. 13, 2020.
Claims priority of provisional application 62/802,754, filed on Feb. 8, 2019.
Prior Publication US 2022/0193003 A1, Jun. 23, 2022
Int. Cl. A61K 31/05 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 31/282 (2006.01); A61K 31/4184 (2006.01); A61K 31/437 (2006.01); A61K 31/4523 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/655 (2006.01); A61K 31/704 (2006.01); A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01); A61P 35/00 (2006.01)

CPC A61K 31/05 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1075 (2013.01); A61K 31/282 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/4523 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/655 (2013.01); A61K 31/704 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01)]

20 Claims

1. A method for inhibiting progression of lung cancer, colorectal cancer, or melanoma in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition that is a nanoemulsion comprising:

i) a single cannabinoid isolate that is a cannabidiol isolate, wherein the cannabidiol isolate is present at a concentration of at least 2% to about 12% w/v;

ii) at least 2% w/v olive oil;

iii) water;

iv) at least 0.05% w/v of polysorbate 80; and

v) terpenes consisting of about 0.25% w/v of each of limonene, myrcene, pinene, and linalool,

wherein the subject is being treated with chemotherapy or is recovering from chemotherapy, and the chemotherapy is a platinum-based agent or dacarbazine.